Skip Navigation LinksHome > June 2013 - Volume 32 - Issue 6 > Antibody Persistence for up to 5 Years After a Fourth Dose o...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e3182840e35
Vaccine Reports

Antibody Persistence for up to 5 Years After a Fourth Dose of Haemophilus influenzae Type b and Neisseria Meningitidis Serogroups C and Y–Tetanus Toxoid Conjugate Vaccine (HibMenCY-TT) Given at 12–15 Months of Age

Marshall, Gary S. MD*; Blatter, Mark MD; Marchant, Colin MD; Aris, Emmanuel PhD§; Mesaros, Narcisa MD§; Miller, Jacqueline M. MD

Supplemental Author Material
Collapse Box

Abstract

Background: A 4-dose series of recently licensed Haemophilus influenzae type b–meningococcal serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) was immunogenic with a clinically acceptable safety profile in infants, with antibodies persisting in most participants for 1 year following dose 4. This study assessed antibody persistence up to 5 years after vaccination.

Methods: Participants had received HibMenCY-TT or Hib-TT at 2, 4 and 6 months of age. At age 12–15 months, HibMenCY-TT vaccinees received a fourth HibMenCY-TT dose (HibMenCY x 4 group), whereas those who received Hib-TT received a fourth dose of either Hib-TT (Hib) or HibMenCY-TT (HibMenCY x 1). Blood samples were collected 1 month and 1, 3 and 5 years after the last dose for measurement of antipolyribosylribitol phosphate (the Hib capsular polysaccharide) antibodies and serum bactericidal activity (human complement source) against meningococcal serogroups C and Y.

Results: Five years after the fourth dose, the percentages of children with antipolyribosylribitol phosphate ≥0.15 μg/mL in HibMenCY x 4, HibMenCY x 1 and Hib groups were 98.8% (95% confidence interval: 93.5%–100%), 97.3% (85.8%–99.9%) and 92.3% (79.1%–98.4%), respectively. The percentages with human complement serum bactericidal activity ≥1:8 for meningococcal serogroup C were 82.9% (72.5%–90.6%), 73.5% (55.6%–87.1%) and 21.1% (9.6%–37.3%), respectively. The percentages with human complement serum bactericidal activity ≥1:8 for serogroup Y were 69.5% (58.4%–79.2%), 54.3% (36.6%–71.2%) and 18.4% (7.7%–34.3%), respectively.

Conclusions: HibMenCY-TT given as a 4-dose series or as a single dose at 12–15 months of age induced immune responses for all 3 antigens that lasted for up to 5 years after vaccination in more than half of recipients.

© 2013 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.